Ocugen, Inc. (OCGN)
OCGNNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$0.9764
+0.0554 (+6.02%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $329.84m
- P/E
- –
- EPS, last 4 quarters
- $-0.2500
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.6909 to $2.73
- Average volume
- 7.45m
- Previous close
- $0.9210
Analysts
5 coveringBuy5 buy, 0 hold, 0 sell
Targets a year out average $10.20, +944.7% from here
Earnings
next estimate $-0.0700Next report
Dec 2025
0.0%
Mar 2026
-20.0%
Jun 2026
-40.0%
Sep 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $1.75m | $1.53m | $1.49m | $1.95m |
| Gross profit | $1.75m | $1.53m | $1.49m | $1.95m |
| Operating income | -$17.63m | -$17.84m | -$16.44m | -$17.75m |
| Net income | -$20.05m | -$19.18m | -$24.88m | -$3.60m |
Last four quarters: revenue $6.72m, margin -1006.8%, free cash flow -$62.91m
News
8 latest- Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock RisesZacks · 5 days ago
- Ocugen Q3 Earnings Call HighlightsMarketBeat · 5 days ago
- Ocugen (OCGN) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- Ocugen (OCGN) Reports Q3 Loss, Tops Revenue EstimatesZacks · 6 days ago
- Ocugen Expands OCU400 Gene Therapy Reach With $255 Mln Milestone Deal RTTNews · Oct 14, 2026
- Ocugen Licenses OCU400 Gene Therapy To Roots Pharmaceutical For MENA Region RTTNews · Oct 14, 2026
- Ocugen Gains Bahamas Approval Pathway For OCU400 Retinitis Pigmentosa Therapy RTTNews · Sep 25, 2026
- Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline AdvancesMarketBeat · Sep 16, 2026
The company
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company's breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen's modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- ocugen.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.